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Introduction
A constantly increasing number of cancer immunotherapies
are being investigated in clinical trials but no reliable bio-
markers to predict clinical beneWt currently exist. For some
cancer types, biomarkers have proven to be meaningful pre-
dictors of patient outcomes (e.g., BCR-ABL in Chronic
Myeloid Leukemia or PSA in prostate cancer) and were
established as routine tools. As eVects of cancer immuno-
therapy are mediated through the immune system, immune
responses may act as natural biomarkers for clinical
eYciency if the right factors can be reliably measured. Fol-
lowing this concept, cancer immunotherapy trials over the
last decade have often included measures of tumor-speciWc
cellular immune responses as endpoints to identify reliable
surrogates for clinical beneWt. Substantial eVorts were
invested throughout the immunotherapy Weld in setting up
suitable cellular immune assays. However, to date, data
from clinical trials do not consistently show that immune
responses are correlated with clinical endpoints [1]. This
lack of correlation is partially interpreted as a consequence
of the high variability in assay results, due to the lack of
assay standardization, validation and harmonization across
laboratories. If harmonization of immune assays can be
achieved, assays can be tested as surrogate endpoints in
clinical trials, substantially accelerate the development of
immunotherapeutic agents and, in addition, oVer a rationale
to pre-select groups of patients with high probability to
beneWt from subsequent immunotherapy.
A plethora of diVerent immunological assays to monitor
antigen-speciWc T cell responses are available, and some are
used by a majority of laboratories. Prime examples are the
ELISPOT assay, intracellular cytokine staining (ICS), MHC-
peptide multimer staining for detection of antigen-speciWc
CD8+ and increasingly for CD4+ T cells and proliferation
assays based on carboxyXuorescein succinimidyl ester
(CFSE)-labelling. Additional functional assays that have
been introduced more recently are based on CD154 up-regu-
lation on activated antigen-speciWc CD4+ T cells or the detec-
tion of CD107a or cytotoxicity related molecules like perforin
or granzyme in CD8+ T cells. For each of these assays, the
use of diVerent protocols that have evolved over time trans-
lates into a wide range of performances. DiVerences in the
interpretation of the results obtained make comparisons of
published data even more complex. This has led to lack of
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comparability as well as doubts about the integrity of the
results that were obtained and published worldwide [2].
Recent developments clearly suggest that “proper”
immunomonitoring will have to encompass the parallel use
of several tests, which together assess the frequency, func-
tion and homing capacity of induced/stimulated T cells
present in the circulation and preferentially also locally
within the targeted tissue. In view of the inXuence of both
natural and adaptive regulatory T cells on clinical outcome,
immunomonitoring should also include screening for these
cells. Only the combined use of several techniques may
lead to a valid set of surrogate markers for speciWc immune
interventions that allows clinical decisions or optimization
of immunotherapeutic strategies. A related proposal was
made by a community-wide consensus workshop on clini-
cal trials with cancer vaccines, in which criteria for the use
of immune assays were recommended including at least
two validated assays to be used in parallel [3].
There is also a surprising disparity between the substan-
tial  Wnancial and logistic eVorts invested in reagents and
man hours to develop immune monitoring techniques and
the comparatively minor investment made to date in actually
validating and standardizing the available techniques within
and between laboratories. This has to be critically re-evalu-
ated as eVorts put in the adequate harmonization of assays
will support the investments already made. They are also a
pre-requisite to meet regulatory requirements on assay stan-
dards prior to them being considered as surrogate endpoints
for clinical trials. This aVects academic institutions and
industry partners alike and may reach beyond cancer into the
Welds of autoimmune and infectious diseases.
How can the immunotherapy community best achieve 
immune assay harmonization?
The goals of harmonization are to identify crucial protocol
choices that inXuence the outcome of an applied assay, and
to standardize those choices across laboratories throughout
the entire Weld for optimal performance and consistent
results. Recent activities in the immunotherapy Weld indi-
cate that there is an increasing awareness of the necessity of
such harmonization and assay validation [4–8]. In parallel
to intra-laboratory standardization, leading to standard
operating procedures (SOP) for a given work setting, large
comparative studies between laboratories with diVerent
protocols are required to identify and standardize crucial
aspects in the protocols used and provide external valida-
tion. Such studies bear various logistical, organisational,
and  Wnancial challenges. A well-coordinated centralized
eVort is necessary to accomplish this goal. ProWciency pan-
els conducted by community-spanning organizations are a
suitable answer.
Over the last 2 years, two non-proWt organizations in
the cancer immunotherapy Weld, the Cancer Vaccine Con-
sortium (CVC) of the Sabin Vaccine Institute and the
Cancer Immunotherapy (CIMT) monitoring panel have
independently initiated large international proWciency
panels. Their Wndings are now being published in two
“technical focus articles” in this issue of CII [9, 10]. Both
studies collected speciWc protocol information from par-
ticipating laboratories and identiWed various protocol
variables, which clearly can inXuence the assay outcome.
Some of them appear to be “common sense” decisions,
but are still neglected by a part of the laboratories in the
immunotherapy  Weld. Most importantly, the Wndings
reported are concordant in both studies, and no contradic-
tion in results is imminent. This is particularly relevant
when taking into account that both panel initiatives chose
a diVerent experimental design. The need to increase the
awareness for harmonization initiatives and external vali-
dation of assay performance is one of the general common
Wndings of both initiatives. SpeciWc recommendations
arising for the ELISPOT from both CVC and CIMT pan-
els are based on the importance of accurate and optimal
number of viable cells added per well, which determine
the sensitivity of the assay. These recommendations
include a resting-phase of cells, the use of automated cell
counters allowing the determination of apoptotic and dead
cell fractions, and an optimal number of cells per well.
Another crucial variable is the unspeciWc stimulation of
cells, which can prevent detection of low frequency T cell
response and demands the use of autologous APC as well
as critical selection of serum sources. Appropriate plate
evaluation strategies and training status of personnel fur-
ther inXuence the assay outcome. These Wndings oVer Wrst
harmonization guidelines that could instantly be accepted
by a broad user base. Further assay optimization can be
accomplished by conducting proWciency panels that spe-
ciWcally focus on the incorporation of identiWed crucial
assay variables.
Historically, the Wrst inter-laboratory testing reports for
ELISPOT were published 7 years ago [11]. Subsequently,
some guidelines resulting from a workshop for assay per-
formance were published about 2 years later [12]. An
important proWciency panel program was initiated by the
NIAID (National Institute of Allergy and Infectious Dis-
eases), Division of AIDS, for the HIV vaccine Weld, which
served as a Wrst model for the CVC panel program [4]. All
these initiatives have certainly attracted attention of the
scientiWc community but have so far not led to broadly
accepted standards for immune monitoring. However,
through the recent proWciency panels of the CIMT and
CVC, which are described in this issue of CII, a chance is
given to harmonize assay criteria within widely applicable
guidelines.Cancer Immunol Immunother (2008) 57:285–288 287
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Cancer immunotherapy networks
It is no co-incidence that both proWciency panels were con-
ducted by community-wide organizations. The history of
unsuccessful individual laboratory or small-scale eVorts has
lead to the idea of joining forces and of establishing non-
proWt organizations that can serve as facilitators of the
required initiatives in the United States and Europe. These
organizations have large networks of members throughout
the immunotherapy community. They (1) give regular
updates on the scientiWc progress, (2) identify the bottle-
necks and the various barriers to future development and (3)
can facilitate the dialogue between the diVerent stakeholders
such as regulatory authorities, pharmaceutical and biotech-
nology companies, academic institutions, patients’ advo-
cacy groups and the public. Without these organizations the
described proWciency panels would not have been possible.
The CVC as part of the Sabin Vaccine Institute initiated
an Assay Working Group, which has conducted two large-
scale ELISPOT proWciency panels over the last 2 years
with access for laboratories world-wide. These served not
only as external validation programs for their participants
(36 laboratories in panel I, and 29 laboratories in panel II),
but also yielded Wrst harmonization steps and guidelines to
standardize and validate this assay as a reliable and widely
acceptable tool for monitoring of immune responses in clin-
ical trials.
The CIMT monitoring panel is a part of the Association
for Immunotherapy of Cancer in Germany. It has until now
initiated and completed two phases of an inter-laboratory
testing project with focus on ELISPOT and tetramer staining
(12 laboratories in panel phase I and 13 laboratories in panel
phase II). The initiative is open for all labs with focus on
immunomonitoring. A two-step approach was established
that facilitates the systematic search for protocol variables
that are predictive for high performance in the assay.
The breadth and size of both programs have the potential
to help shape immune assay standardization and validation,
and serve the ultimate goal of assay harmonization. Collab-
oration between both groups has proven meaningful for this
Wrst round of testing and is planned to increase for future
activities.
Perspective
The conducted proWciency panels represent the largest
inter-laboratory testing projects in this Weld to date. They
provide Wrst harmonization guidelines for ELISPOT assay
and Tetramer staining. In addition, they demonstrate that
international collaboration on this scale driven by non-
proWt organizations is feasible and forms the basis for
expanded future initiatives. Consequently, new ProWciency
Panels are now being started or are already under way.
They include for CVC: ELISPOT, Tetramer, ICS and
CFSE-labelling, and for CIMT: Elispot, Tetramer, ICS.
Presentations during the coming annual meetings of both
organizations will focus on recent developments and new
technologies in the Weld. First guidelines for validation and
training beyond this publication as well as for assay accep-
tance are in preparation. Additional organisational struc-
tures are now being established to oVer the possibility of
regular participation in diVerent panels to the increasing
number of laboratories world-wide that are seeing the value
in assay harmonization. Aims are to Wnd standards for train-
ing of staV, requirements for handling and test performance
and for generating, measuring and reporting of data in
broadly available technologies.
With the larger picture in mind, harmonization of these
assays may provide the immunotherapy community with
valuable surrogate markers for developing new therapies in
clinical trials. This may ultimately help improving the clin-
ical success of immunotherapies and bring them to patients
more expeditiously.
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